Suggestions
Cassandre Joseph
Global Head of Talent Acquisition R&D @ Novartis | Pharmaceuticals
Cassandre Joseph is a highly experienced talent acquisition professional with a strong background in the life sciences industry. With a Master of Science degree in Biology from New York University and a Bachelor's degree in Biology and Political Science from Rutgers University, Cassandre possesses a unique blend of scientific and political knowledge.
Cassandre has held numerous senior-level roles in talent acquisition, including Head of US Talent Acquisition at global healthcare company Novartis. She has also worked as a Program Manager at Korn Ferry and Senior Talent Acquisition Consultant at companies like Alcon, Ortho Clinical Diagnostics, and Johnson & Johnson. Additionally, she has worked as a Talent Acquisition Partner at Integra Lifesciences and as a Senior Recruiter at Kelly Services.
Throughout her career, Cassandre has developed a versatile set of skills, including sourcing, recruiting, client and candidate management, and process improvement. She is also an expert in developing recruitment strategies, leveraging technology, and implementing diversity and inclusion initiatives.
Overall, Cassandre is a seasoned talent acquisition professional with a strong background in the life sciences industry. Her combination of scientific expertise and political savvy has made her a valuable asset to the organizations she has worked with.
Highlights
Driven by a unified purpose to impact the lives of people living with advanced cancers, Novartis is working to create a future where every eligible patient can receive radioligand therapies (RLTs) not just today—but into the future. Learn more about this commitment to RLT: https://lnkd.in/g8JcTs7A Look for opportunities to join us here: https://lnkd.in/eeYr5Cw #ASCO24 #NovartisTogether #NovartisCareers
Hope and science are a powerful combination. Twenty-five years ago, malaria treatments were failing. Patients were taking medicine but weren’t getting better. The situation was dire. Working with Chinese partners, Novartis launched a new therapy in 1999 that transformed the treatment of malaria and contributed – along with prevention tools and better diagnostics – to averting 2 billion cases and saving nearly 12 million lives. But progress has stalled, and increasing resistance to existing agents threatens these hard-won gains. It’s time to act if we want to make malaria a problem of the past. #WHA77 #EndMalaria #Malaria #NovartisTogether Michael Adekunle Charles | Abdisalan M. Noor | Thierry Diagana | Nekoye Otsyula | RBM Partnership to End Malaria | Bernhards Ogutu | Harvard T.H. Chan School of Public Health
Learn more: https://lnkd.in/g78kZq-4 Join us: https://lnkd.in/eeYr5Cw
